Status:
UNKNOWN
Diagnostic Performance Indicators in Upper GI Endoscopy:PROSPERO Study
Lead Sponsor:
University of Cambridge
Collaborating Sponsors:
Cambridge University Hospitals NHS Foundation Trust
Conditions:
Esophageal Cancer
Gastric Cancer
Eligibility:
All Genders
18+ years
Brief Summary
Cancers of the upper gastro-intestinal tract, including esophagus (gullet), stomach and small bowel, are amongst the deadliest malignancies. The main reason for their high mortality rate is that they ...
Detailed Description
BACKGROUND Esophagogastroduodenoscopy (EGD) is the gold-standard test for investigating upper gastrointestinal (GI) tract pathology. The learning curve for EGD is generally steep and it is often perfo...
Eligibility Criteria
Inclusion
- Able to read, comprehend, and complete the consent form
- Aged ≥18
- Clinically fit for endoscopy
- Referred for endoscopy via any clinical pathway
Exclusion
- Known upper GI conditions with or without ongoing endoscopic monitoring including Barrett's oesophagus, oesophageal dysplasia, gastric ulcers, duodenal polyps or any established upper GI malignancy
- Previous oesophagectomy, gastrectomy for malignant disease
- OGD performed within last 3 years of study initiation
- Oesophageal stricture precluding completion of diagnostic endoscopic examination
- Coagulopathy or anticoagulant/antiplatelet therapy for high risk conditions making non possible to discontinue the medication
Key Trial Info
Start Date :
June 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 15 2022
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT04843397
Start Date
June 1 2021
End Date
September 15 2022
Last Update
April 15 2021
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.